Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment
William Shipman, Katelyn Singh, Jeffrey M. Cohen, Jonathan S. Leventhal, William Damsky, Mary M. Tomayko
Abstract
Immune checkpoint inhibitor-induced bullous pemphigoid (ICI-BP) is a clinically debilitating immune-related adverse event in need of novel therapeutic approaches, as conventional treatment can counteract intended tumour immunity. Here we demonstrate that interleukin (IL)-4 and IL-13 expression is elevated in ICI-BP similar to conventional autoimmune BP, and further demonstrate partial and complete disease clearance with dupilumab in four patients with ICI-BP. These data indicate that IL-4Rα inhibition may be a promising new therapy for ICI-BP.
Topics & Concepts
Bullous pemphigoidDupilumabMedicineImmune systemImmunologyPemphigoidInterleukinInterleukin 15ImmunotherapyAdverse effectInterleukin 2Immune checkpointAutoimmune diseaseAntibodyInternal medicineCytokineAtopic dermatitisAutoimmune Bullous Skin DiseasesUrticaria and Related ConditionsCoagulation, Bradykinin, Polyphosphates, and Angioedema